Alpha 2.0
Login Register
» Articles » PMID: 30813407

The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2019 Mar 1
PMID 30813407
Citations 36
Authors
Beatriz G de la Torre
Fernando Albericio
Affiliations
Soon will be listed here.
Abstract

The Food and Drug Administration approved 59 new drugs (42 New Chemical Entities and 17 Biologics) during 2018. This number breaks the previous record of 53 approved by the same organization in 1996. The 17 new biologics approved in 2018 also represent an important milestone for this kind of drug and they clearly exceed the 12 approved in 2015 and 2017. Herein, the 59 new drugs of the class of 2018 are analyzed from a strictly chemical perspective. The classification has been carried out on the basis of the chemical structure and includes the following: Biologics (antibodies and enzymes); TIDES (peptides and oligonucleotides) and natural products; drug combinations; and small molecules.

Citing Articles

Extract Mitigates Doxorubicin-Induced Hepatotoxicity in Male Rats.

Alsirhani A, Abu-Almakarem A, Alwaili M, Aljohani S, Alali I, AlRashidi A Int J Mol Sci. 2024; 25(23).

PMID: 39684253 PMC: 11641798. DOI: 10.3390/ijms252312541.

Perspectives on Applications of F-NMR in Fragment-Based Drug Discovery.

Li Q, Kang C Molecules. 2024; 29(23).

PMID: 39683906 PMC: 11643073. DOI: 10.3390/molecules29235748.

Impact of N-Terminal PEGylation on Synthesis and Purification of Peptide-Based Cancer Epitopes for Pancreatic Ductal Adenocarcinoma (PDAC).

Luna O, Perez Y, Ferrari D, Sayedipour S, Royo M, Acosta G ACS Omega. 2024; 9(32):34544-34554.

PMID: 39157077 PMC: 11325526. DOI: 10.1021/acsomega.4c02604.

Advancements in clinical RNA therapeutics: Present developments and prospective outlooks.

Saw P, Song E Cell Rep Med. 2024; 5(5):101555.

PMID: 38744276 PMC: 11148805. DOI: 10.1016/j.xcrm.2024.101555.

The landscape of nanoparticle-based siRNA delivery and therapeutic development.

Moazzam M, Zhang M, Hussain A, Yu X, Huang J, Huang Y Mol Ther. 2024; 32(2):284-312.

PMID: 38204162 PMC: 10861989. DOI: 10.1016/j.ymthe.2024.01.005.

References
1.
Reichert J . Antibodies to watch in 2017. MAbs. 2016; 9(2):167-181. PMC: 5297518. DOI: 10.1080/19420862.2016.1269580. View
2.
Mullard A . 2016 FDA drug approvals. Nat Rev Drug Discov. 2017; 16(2):73-76. DOI: 10.1038/nrd.2017.14. View
3.
de la Torre B, Albericio F . The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type. Molecules. 2017; 22(3). PMC: 6155368. DOI: 10.3390/molecules22030368. View
4.
Beck A, Goetsch L, Dumontet C, Corvaia N . Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017; 16(5):315-337. DOI: 10.1038/nrd.2016.268. View
5.
Mullard A . 2017 FDA drug approvals. Nat Rev Drug Discov. 2018; 17(2):81-85. DOI: 10.1038/nrd.2018.4. View